RETRACTED ARTICLE: Effects of Dapagliflozin on myocardial remodeling, inflammatory factors, and cardiac events in heart failure with preserved ejection fraction

To investigate the effects of Dapagliflozin on myocardial remodeling, inflammatory factors, and cardiac events in the treatment of heart failure with preserved ejection fraction (HFpEF). Ninety-two patients with HFpEF treated in our hospital from August 2021 to March 2022 were retrospectively picked as study subjects. These subjects were randomized as the study group and control group following the random number table, with 46 cases in each group. Patients in the control group adopted standard anti-heart failure (HF) treatment, including diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists β receptor blockers, and digitalis. Patients in the study group received Dapagliflozin on the basis of the control group. Changes in myocardial remodeling-related parameters [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), the ratio of early diastolic blood flow velocity to late diastolic blood flow velocity (E/A), plasma N-terminal B-type brain natriuretic peptide precursor (NT-proBNP), and cardiac troponin I (CTnI)] were assessed by echocardiography before and 12 months after the intervention. The content of inflammatory factors [interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6)] in serum was measured by enzyme-linked immunosorbent assay. The factors affecting the clinical efficacy of Dapagliflozin were analyzed by the multivariate logistic regression. The incidence of cardiac events was compared between the two groups. The effective rate of 95.65% in the study group was much higher than 80.43% in the control group ( P < 0.05). After the intervention, the study group had an especially higher content of LVEF and E/A and sharply lower content of LVEDD, NT-proBNP, and CTnI than the control group ( P < 0.001). After the intervention, IL-1β, TNF-α, and IL-6 levels were markedly lower in the study group than in the control group ( P < 0.001). The incidence of cardiac events, including arrhythmias, recurrent angina, heart failure rehospitalization, cardiogenic death, and all-cause mortality, was 8.70% in the study group and 26.09% in the control group, which was much lower in the study group ( P < 0.05). The results of multivariate logistic regression analysis showed that LVEF and E/A were independent protective factors affecting the ineffectiveness of Dapagliflozin ( P < 0.05), and LVEDD, NT-proBNP, CTnI, IL-1β, TNF-α, and IL-6 were independent risk factors affecting the ineffectiveness of Dapagliflozin ( P < 0.05). In conclusion, Dapagliflozin could effectively improve myocardial remodeling, inhibit inflammatory reaction, and play a more active role in the treatment of patients with HFpEF, providing a certain clinical basis for the treatment of patients.